Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 7, 2026; 32(25): 119588
Published online Jul 7, 2026. doi: 10.3748/wjg.119588
Published online Jul 7, 2026. doi: 10.3748/wjg.119588
CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy
Ze-Hao Zheng, Rui Xiao, Na Liu, Ben-Yi He, Wei Yu, Min-Shan Chen, Jie Mei, Dan-Dan Hu, Rong-Ping Guo, Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Zhong-Shi Wu, Department of General Surgery, Clifford Hospital, Jinan University, Guangzhou 511495, Guangdong Province, China
Rong-Ping Guo, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Rong-Ping Guo, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Co-first authors: Ze-Hao Zheng and Rui Xiao.
Co-corresponding authors: Dan-Dan Hu and Rong-Ping Guo.
Author contributions: Zheng ZH, Xiao R, and Liu N designed the study and drafted the manuscript; Zheng ZH, Xiao R, Liu N, and He BY participated in data collection and analysis; Zheng ZH and Xiao R made significant contributions to this study and should be considered co-first authors; Yu W helped draw the figures; Guo RP, Chen MS, and Hu DD provided financial support; Hu DD and Guo RP supervised the study; Hu DD and Guo RP provided significant support in academic decision-making and content guidance and they contribute equally to this study as co-corresponding authors; all the authors have read and approved the final version of the manuscript.
Supported by the National Science and Technology Major Project of China, No. 2024ZD0520402; and Science and Technology Planning Project of Guangzhou, No. 2023A03J0601.
Institutional review board statement: This study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center (Approval No. B2025-237-01).
Informed consent statement: The informed consent was waived by the Institutional Review Board.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: The datasets of the current study are available from the corresponding author on reasonable request.
Corresponding author: Rong-Ping Guo, Department of Liver Surgery, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou 510060, Guangdong Province, China. guorp@sysucc.org.cn
Received: February 2, 2026
Revised: February 19, 2026
Accepted: March 13, 2026
Published online: July 7, 2026
Processing time: 150 Days and 23.7 Hours
Revised: February 19, 2026
Accepted: March 13, 2026
Published online: July 7, 2026
Processing time: 150 Days and 23.7 Hours
Core Tip
Core Tip: This study validated the prognostic value of the CRAPT-M model in patients with hepatocellular carcinoma receiving locoregional-bevacizumab-immunotherapy. The model effectively stratified overall survival and progression-free survival not only in the locoregional plus atezolizumab plus bevacizumab group but also in the locoregional plus sintilimab plus bevacizumab group. In addition, we developed a Simple-CRAPT-M model based on the number of risk factors, which may provide a more convenient tool for rapid risk stratification in clinical practice.